Brave new world for interventional bronchoscopy

Toma, I. P.; Gecides, D. M.; Shah, P. L.
March 2005
Thorax;Mar2005, Vol. 60 Issue 3, p180
Academic Journal
The article focuses on interventional bronchoscopy. Bronchial thermoplasty for the treatment of asthma is close to receiving the U.S. Food & Drug Administration approval. A number of procedures are being developed to improve breathlessness in severe emphysema. These aim to achieve volume reduction by bronchoscopy rather than surgery. While bronchoscopic valve placement has been proposed for patchy emphysema, an alternative intervention has been suggested for diffuse emphysema.


Related Articles

  • FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease.  // Biomedical Market Newsletter;7/5/2011, p4 

    The article reports that on July 1, 2011, Arcapta Neohaler was approved by the U.S. Food and Drug Administration (FDA) for treatment of people suffering from airflow obstruction caused by chronic obstructive pulmonary disease (COPD). It says that Arcapta Neohaler relaxes muscles around the...

  • Neutrophil airway inflammation in childhood asthma. McDougall, C.M.; Helms, P. J. // Thorax;Sep2006, Vol. 61 Issue 9, p739 

    The article reflects on the neutrophilic airway inflammation in childhood in asthma. The author noted that inflammation is more common in children yet less severe compared to the airway inflammation among adolescents and adults. Findings of high prevalence among children may have been...

  • Theophylline.  // Reactions Weekly;9/1/2007, Issue 1167, p26 

    The article presents a case report of a woman who, during treatment with theophylline for asthma, developed hypercalcaemia. The woman started receiving theophylline 200 mg/day internally at the age of 46 years in 1998. She had been receiving prednisolone for 10 years and after being diagnosed...

  • Asthmatx in expedited review of asthma device therapy PMA. LONG, DON // Medical Device Daily;1/22/2009, Vol. 13 Issue 13, p1 

    The article reports on the announcement by Asthmatx that it has filed the final module of its PMA application for its Alair Bronchial Thermoplasty system for treating severe asthma. The U.S. Food and Drug Administration (FDA) has granted the system expedited review status. The new device system...

  • AstraZeneca submits Symbicort for COPD indication.  // Pharmacy Today;Jun2008, Vol. 14 Issue 6, p1 

    The article elaborates the submission of a supplemental new drug application for Symbicort by AstraZeneca in the U.S. It was submitted to the Food and Drug Administration as a treatment for chronic obstructive pulmonary disease (COPD). At present, the drug was used as a treatment of asthma but...

  • New Asthma Medication for Infants and Children. Preboth, Monica // American Family Physician;3/15/2001, Vol. 63 Issue 6, p1237 

    Reports on the approval of budesonide inhalation suspension, a new asthma medication, for infants and young children by the United States Food and Drug Administration. Description of budesonide inhalation suspension; How the medication should be administered.

  • Validity of instruments to measure physical activity may be questionable due to a lack of conceptual frameworks: a systematic review.  // Health & Quality of Life Outcomes;2011, Vol. 9 Issue 1, p86 

    The article offers information on a study conducted to identify conceptual frameworks of physical activity in chronic respiratory patients, and the development of patient-reported outcomes (PROs) or measuring physical activity. It states that data was extracted from the Internet, on heart...

  • Asthma Education Reduces Readmission Rate. Barry, Henry // American Family Physician;3/15/2004, Vol. 69 Issue 6, p1507 

    Answers the question about whether a multiphasic intervention can reduce the rate or readmission among patients with asthma who frequently require health care services. Description of a study of asthma patients; Conclusion that for adults with asthma who have had at least one previous...

  • The use and abuse of office spirometry. Enright, Paul // Primary Care Respiratory Journal;Dec2008, Vol. 17 Issue 4, p238 

    Spirometry programs (outside of primary care settings) designed to detect COPD in the general adult population are not justified, since the true positive yield (airway obstruction with an FEV1 below 60% predicted) is very low, and the false positive rate is very high. However, spirometry is...


Read the Article


Sign out of this library

Other Topics